PWAM
CSTL icon

Park West Asset Management’s Castle Biosciences CSTL Stock Holding History

Park West Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-556,485
Closed -$11.1M – 47
2025
Q1 		$11.1M Buy
+556,485
New +$13.8M 0.9% 37

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Park West Asset Management's CSTL Position: Q2 2025 in Review

Park West Asset Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 556,485 shares — an estimated $11.1M sold.

Park West Asset Management first reported a position in CSTL in Q1 2025 and held it in 1 quarter. The position peaked at $11.1M in Q1 2025. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Park West Asset Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Park West Asset Management sold 556,485 Castle Biosciences shares in Q2 2025, an estimated $11.1M.
  • Park West Asset Management first reported a position in Castle Biosciences in Q1 2025 and held it in 1 quarter.
  • Park West Asset Management's Castle Biosciences position peaked at $11.1M in Q1 2025.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Park West Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.